Quanterix Q4 revenue rises 25%

Quanterix

02/03/2026 21:10

Overview

Biomarker detection firm's Q4 revenue rose 25% yr/yr

Company expects cash flow breakeven in 2026

Submitted FDA notification for Alzheimer's blood test

Outlook

Quanterix expects 2026 revenue of $169 to $174 mln

Company anticipates cash flow breakeven in second half of 2026

Quanterix expects to end 2026 with $100 mln in cash and no debt

Result Drivers

PRODUCT REVENUE GROWTH - Q4 revenue increased 25% yr/yr, driven by product revenue growth

COST SAVINGS - Implemented $74 mln of cost savings related to Akoya transaction, with 94% of integration milestones complete

Company press release: ID:nBw5QkcNCa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$29.22 mln
Q4 Net Income
-$23.12 mln
Q4 Basic EPS
-$0.49
Q4 Gross Profit
$20.04 mln
Q4 Operating Expenses
$44.79 mln
Q4 Operating Income
-$24.75 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Quanterix Corp is $7.50, about 14.5% above its February 27 closing price of $6.55

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)